Retatrutide Clinical Results 2026: From 24% to 28.7% Weight Loss

What's New: June 2026 Update

• TRIUMPH-4 confirmed as final: 28.7% weight loss at 68 weeks — peer-reviewed Phase 3 data, not a press release estimate
• TRIUMPH-1 CONFIRMED (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients — the pivotal general obesity trial met all primary and key secondary endpoints
• TRIUMPH-1 extension: In a prespecified 104-week extension, patients reached 30.3% average weight loss — confirming weight loss does not plateau at 80 weeks
• TRIUMPH-2 (diabetes + obesity): Results expected Q3–Q4 2026
• NDA submission on track: Eli Lilly confirmed Q4 2026 filing target on Q1 2026 earnings call
  ‍

Introduction

Retatrutide's clinical journey tells a story of escalating efficacy. Phase 2 trials published in 2023 showed 24% weight loss — impressive enough to generate global attention. Then came TRIUMPH-4 in December 2025: 28.7% weight loss at 68 weeks, approaching bariatric surgery outcomes without the scalpel. Then TRIUMPH-1 in May 2026: 28.3% in 2,339 general obesity patients at 80 weeks, confirming the results are consistent and reproducible across a much larger, more representative population.

This isn't incremental improvement. It's a paradigm shift. We've gone from GLP-1 single agonists producing 15% weight loss (semaglutide), to dual agonists achieving 22.5% (tirzepatide), to retatrutide's triple mechanism delivering nearly 30%. More importantly, 58.6% of participants in TRIUMPH-4 achieved ≥25% weight loss — outcomes traditionally seen only with surgery. TRIUMPH-1 confirmed a 45.3% rate of ≥30% weight loss in the general obesity population.

This article analyzes the complete clinical dataset: Phase 2 results from 2023, TRIUMPH-4 Phase 3 data from December 2025, TRIUMPH-1 Phase 3 data from May 2026, safety profiles, mechanism insights, and what the remaining TRIUMPH trials might reveal.

Efficacy Summary Across All Completed Trials

Phase 2: The Foundation (2023)

The Phase 2 trial, published in the New England Journal of Medicine in June 2023, evaluated retatrutide in 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities. The study tested multiple doses (1mg, 4mg, 8mg, 12mg) against placebo over 48 weeks.

Phase 2 Weight Loss Results by Dose

The dose-response relationship was clear: higher doses produced progressively greater weight loss. The 12mg dose became the focus for Phase 3 development.

Phase 2 Responder Rates (12mg Dose)

• ≥15% weight loss: 83% of participants (vs. 9% placebo)
• ≥20% weight loss: 45% of participants (vs. 0% placebo)
• ≥30% weight loss: 6% of participants (vs. 0% placebo)

Phase 2 Safety Profile

Most GI side effects occurred during dose escalation (weeks 1–20) and improved thereafter. Discontinuation rate: 10.6% at 12mg dose due to adverse events.

Phase 2 Metabolic Benefits

Beyond weight loss, retatrutide improved cardiometabolic markers:

• Blood pressure: Systolic BP decreased 7.4 mmHg (12mg dose)
• Triglycerides: Reduced 27% from baseline
• HDL cholesterol: Increased 18%
• Fasting glucose: Decreased 13.8 mg/dL
• HbA1c: Reduced 0.4% (in participants without diabetes)

TRIUMPH-4: Phase 3 Breakthrough (December 2025)

TRIUMPH-4 was the first Phase 3 trial to report, and it exceeded Phase 2 results. The trial enrolled 751 adults with obesity and moderate-to-severe knee osteoarthritis pain, evaluating whether retatrutide could simultaneously induce weight loss and reduce joint pain.

TRIUMPH-4 Primary Results (68 Weeks)

TRIUMPH-4 Dose Arms

TRIUMPH-4: Beyond Weight Loss

Participants experienced substantial pain reduction on the WOMAC scale:

• Pain subscale: Improved 44 points vs. 13 points placebo
• Physical function: Improved 41 points vs. 12 points placebo
• 6-minute walk distance: Increased 63 meters (vs. 12 meters placebo)
• IWQOL-Lite total score: +25 points (vs. +5 placebo)

TRIUMPH-1: The Pivotal General Obesity Trial (May 2026)

TRIUMPH-1 is the most important trial in the program for FDA purposes. Unlike TRIUMPH-4, which enrolled patients with knee osteoarthritis, TRIUMPH-1 enrolled 2,339 adults with general obesity (no required comorbidity) — the broad population retatrutide will be prescribed to after approval.

Why TRIUMPH-1 Matters More Than TRIUMPH-4

TRIUMPH-4 answered the question "does retatrutide work?" TRIUMPH-1 answered the question "does retatrutide work consistently across a large, diverse obesity population?" The answer, confirmed on May 21, 2026, is yes.

With 2,339 participants — more than three times the TRIUMPH-4 population — TRIUMPH-1 provides the statistical power needed to confirm efficacy and detect rare safety signals. This is the dataset Eli Lilly will anchor their NDA submission on.

TRIUMPH-1 Primary Results (80 Weeks)

TRIUMPH-1: 104-Week Extension

In a prespecified extension for participants with BMI ≥35, average weight loss reached 30.3% at 104 weeks. This confirms that weight loss does not plateau at 80 weeks — patients who continue treatment can expect further improvement.

The 30.3% result is significant: it crosses into territory previously associated only with bariatric surgery (typically 25–35% at 1–2 years).

TRIUMPH-1 vs. TRIUMPH-4: What the Comparison Shows

Key takeaway: The two trials show nearly identical efficacy (28.7% vs. 28.3%) across different populations and durations. TRIUMPH-1's lower discontinuation rate (11.3% vs. 18.2%) is encouraging — it suggests that in a general obesity population without additional comorbidities, tolerability is better than in TRIUMPH-4. This is consistent with TRIUMPH-1's slightly more gradual titration protocol.

Safety Profile: All Completed Trials

Gastrointestinal Side Effects

The trend is clear: GI side effect rates have declined across trials as dose escalation protocols improved. Phase 2 used aggressive titration; TRIUMPH-4 and TRIUMPH-1 both used more gradual protocols with better tolerability outcomes.

Discontinuation Rates

TRIUMPH-1's 11.3% discontinuation rate is an important improvement over TRIUMPH-4's 18.2%. The difference is likely explained by population (general obesity vs. obesity with osteoarthritis), protocol refinements, and longer experience managing retatrutide side effects.

Dysesthesia

TRIUMPH-4 revealed a unique side effect: dysesthesia (abnormal sensations like tingling, burning, or numbness) in 20.9% of participants. This is hypothesized to relate to glucagon receptor activation.

TRIUMPH-1 confirmed dysesthesia as a class-level finding. Most cases were mild to moderate, and 2.1% of TRIUMPH-4 participants discontinued specifically due to dysesthesia.

Mechanism: Why Triple Agonism Works

Retatrutide targets three receptors simultaneously:

GLP-1 Receptor: Reduces appetite, slows gastric emptying, enhances insulin secretion. Contributes ~40–50% of total weight loss effect.

GIP Receptor: Synergizes with GLP-1 for insulin secretion, improves lipid metabolism, reduces food intake through central pathways. Contributes ~30–40% of total effect.

Glucagon Receptor: Increases energy expenditure, promotes fat oxidation (lipolysis), may counteract metabolic adaptation. Contributes ~20–30% of total effect — this is the unique mechanism that separates retatrutide from tirzepatide.

Traditional concerns about glucagon (hyperglycemia) are mitigated by the simultaneous GLP-1/GIP activation, which suppresses glucagon's negative metabolic effects while preserving its beneficial thermogenic actions.

Comparison to Other Obesity Medications

For the complete side-by-side comparison of all three drugs across all metrics, see our comparison of retatrutide vs tirzepatide vs semaglutide.

What We Still Don't Know

Longer-Term Data Beyond 104 Weeks

TRIUMPH-1's extension reached 104 weeks with 30.3% weight loss. Does loss continue beyond 2 years, or does it plateau? No data yet.

Weight Regain After Discontinuation

All GLP-1 medications show substantial weight regain when stopped. TRIUMPH-5 (weight maintenance trial) is ongoing and will address this.

Cardiovascular Outcomes

TRIUMPH-CVOT won't report until 2028–2029. FDA will scrutinize TRIUMPH-1 and TRIUMPH-4 for any cardiovascular safety signals.

Dysesthesia Long-Term Impact

Is dysesthesia transient or persistent? Does it represent nerve damage or benign sensory adaptation? Longer follow-up is needed.

Real-World Tolerability

Clinical trials provide intensive support. Real-world discontinuation rates may differ from the 11.3% seen in TRIUMPH-1.

Clinical Implications

Who Should Consider Retatrutide (When Approved)?

Ideal candidates:

• BMI ≥35–40 (severe obesity)
• Failed or inadequate response to semaglutide or tirzepatide (<10% weight loss)
• Seeking maximal weight loss to avoid or delay bariatric surgery
• Willing to tolerate higher side effect rates for superior efficacy

Less ideal candidates:

• BMI 27–30 (mild obesity) — efficacy advantage may not justify tolerability trade-off
• History of pancreatitis or gallbladder disease
• Intolerance to GLP-1 medications

For month-by-month expectations of what weight loss looks like in practice, see our retatrutide weight loss timeline.

Conclusion

Three completed trials now confirm retatrutide's efficacy across different populations, doses, and durations:

• Phase 2 (338 patients, 48 weeks): 24.2% — proof of concept
• TRIUMPH-4 (751 patients, 68 weeks): 28.7% — first Phase 3 confirmation
• TRIUMPH-1 (2,339 patients, 80 weeks): 28.3% — pivotal confirmation in general obesity population
• TRIUMPH-1 extension (subset, 104 weeks): 30.3% — weight loss continues beyond 80 weeks

The consistency across TRIUMPH-4 (28.7%) and TRIUMPH-1 (28.3%) across two very different populations is the most important finding. It means the results aren't driven by population-specific factors — they reflect the drug's fundamental mechanism.

With TRIUMPH-1 complete, Eli Lilly now has the data required for NDA submission, anticipated Q4 2026. For the current FDA approval timeline, see our current FDA approval status.

The data is in. Retatrutide is the most effective obesity medication ever tested in Phase 3 trials.

Sources

• Eli Lilly press release: TRIUMPH-1 Phase 3 topline results. May 21, 2026.
• Eli Lilly TRIUMPH-4 Phase 3 Trial Results. December 2025.
• Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity." NEJM 2023;389:514–526
• FDA Prescription Drug User Fee Act (PDUFA) Guidelines
• ClinicalTrials.gov: TRIUMPH Phase 3 program trial registry
• Eli Lilly Investor Relations: Q1 2026 earnings call